Generics in Germany

Generics in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Germany generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The German generics market is expected to generate total revenues of $10.0bn in 2015, representing a compound annual growth rate (CAGR) of 1.7% between 2011 and 2015.

Market consumption volume is forecast to reach a total of 87.8 % of total pharma volume in 2015.

Germany has the highest generics volume share in Western Europe, but there is still room for growth, especially as more drugs come off patent.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Germany

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Germany

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Germany generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Germany economy

Reasons to buy

What was the size of the Germany generics market by value in 2015?

What will be the size of the Germany generics market in 2020?

What factors are affecting the strength of competition in the Germany generics market?

How has the market performed over the last five years?

How large is Germany’s generics market in relation to its regional counterparts?

Companies mentioned

Mylan Inc., Sandoz International GmbH, STADA Arzneimittel AG, Teva Pharmaceutical Industries Limited

Table of Contents

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market volume 9

Market Segmentation 10

Geography segmentation 10

Market Outlook 11

Market value forecast 11

Market volume forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 15

New entrants 16

Threat of substitutes 17

Degree of rivalry 18

Leading Companies 19

Mylan Inc. 19

Sandoz International GmbH 22

STADA Arzneimittel AG 23

Teva Pharmaceutical Industries Limited 26

Macroeconomic Indicators 29

Country Data 29

Methodology 31

Industry associations 32

Related MarketLine research 32

Appendix 33

About MarketLine 33

List of Tables

Table 1: Germany generics market value: $ billion, 201115(e)

Table 2: Germany generics market volume: % of total pharma volume, 201115(e)

Table 3: Germany generics market geography segmentation: $ billion, 2015(e)

Table 4: Germany generics market value forecast: $ billion, 201520

Table 5: Germany generics market volume forecast: % of total pharma volume, 201520

Table 6: Mylan Inc.: key facts

Table 7: Mylan Inc.: key financials ($)

Table 8: Mylan Inc.: key financial ratios

Table 9: Sandoz International GmbH: key facts

Table 10: STADA Arzneimittel AG: key facts

Table 11: STADA Arzneimittel AG: key financials ($)

Table 12: STADA Arzneimittel AG: key financials (€)

Table 13: STADA Arzneimittel AG: key financial ratios

Table 14: Teva Pharmaceutical Industries Limited: key facts

Table 15: Teva Pharmaceutical Industries Limited: key financials ($)

Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

Table 17: Germany size of population (million), 201115

Table 18: Germany gdp (constant 2005 prices, $ billion), 201115

Table 19: Germany gdp (current prices, $ billion), 201115

Table 20: Germany inflation, 201115

Table 21: Germany consumer price index (absolute), 201115

Table 22: Germany exchange rate, 201115

List of Figures

Figure 1: Germany generics market value: $ billion, 201115(e)

Figure 2: Germany generics market volume: % of total pharma volume, 201115(e)

Figure 3: Germany generics market geography segmentation: % share, by value, 2015(e)

Figure 4: Germany generics market value forecast: $ billion, 201520

Figure 5: Germany generics market volume forecast: % of total pharma volume, 201520

Figure 6: Forces driving competition in the generics market in Germany, 2015

Figure 7: Drivers of buyer power in the generics market in Germany, 2015

Figure 8: Drivers of supplier power in the generics market in Germany, 2015

Figure 9: Factors influencing the likelihood of new entrants in the generics market in Germany, 2015

Figure 10: Factors influencing the threat of substitutes in the generics market in Germany, 2015

Figure 11: Drivers of degree of rivalry in the generics market in Germany, 2015

Figure 12: Mylan Inc.: revenues & profitability

Figure 13: Mylan Inc.: assets & liabilities

Figure 14: STADA Arzneimittel AG: revenues & profitability

Figure 15: STADA Arzneimittel AG: assets & liabilities

Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

List of Tables

NA

List of Figures

NA

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports